Milnacypran: interakcje

Avoid concomitant use of milnacipran hydrochloride in patients with substantial alcohol use or chronic liver disease ( 5.6 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), including milnacipran hydrochloride, can precipitate serotonin syndrome, a potentially life-threatening condition. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

In addition, do not start milnacipran hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 , 5.2 ). (etykieta leku Milnacypran, Przeciwwskazania)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina, Interakcje z innymi lekami)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina + nalokson, Interakcje z innymi lekami)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina + kodeina, Interakcje z innymi lekami)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Butalbital + paracetamol + kofeina + kodeina, Interakcje z innymi lekami)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Butorfanol, Środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (etykieta leku Deksamfetamina, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Avoid co-administration of milnacipran hydrochloride and intravenous digoxin [see Warnings and Precautions ( 5.3 , 5.4 )] . (etykieta leku Milnacypran, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Łączenie dziurawca z lekami przeciwdepresyjnymi i innymi lekami serotoninergicznymi zwiększa ryzyko zespołu serotoninowego. (NCCIH, St. John's Wort)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (etykieta leku Edoksaban, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (etykieta leku Milnacypran, Przeciwwskazania)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon, Interakcje z innymi lekami)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + chlorfenamina, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + homatropina, Interakcje z innymi lekami)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + ibuprofen, Środki ostrożności)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + paracetamol, Środki ostrożności)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydromorfon, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (etykieta leku Milnacypran, Przeciwwskazania)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Kodeina, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Leworfanol, Środki ostrożności)

In addition, do not start milnacipran hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 , 5.2 ). (etykieta leku Milnacypran, Przeciwwskazania)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Lisdeksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Metadon, Ostrzeżenia i środki ostrożności)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (etykieta leku Metaksalon, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Metamfetamina, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Morfina, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (etykieta leku Oksykodon, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Oksymorfon, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Olicerydyna, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Paracetamol + kodeina, Środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Pentazocyna + nalokson, Środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Pokrzyk wilcza jagoda (belladonna) + opium, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Prometazyna + kodeina, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (etykieta leku Milnacypran, Przeciwwskazania)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Remifentanyl, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (etykieta leku Milnacypran, Przeciwwskazania)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (etykieta leku Milnacypran, Przeciwwskazania)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), including milnacipran hydrochloride, can precipitate serotonin syndrome, a potentially life-threatening condition. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Zyprazydon, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (etykieta leku Milnacypran, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (etykieta leku Milnacypran, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (etykieta leku Milnacypran, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (etykieta leku Milnacypran, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (etykieta leku Milnacypran, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (etykieta leku Nalbufina, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (etykieta leku Milnacypran, Interakcje z innymi lekami)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Milnacypran, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Clonidine: Because milnacipran hydrochloride inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine’s anti-hypertensive effect. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Milnacypran, Interakcje z innymi lekami)

Clinical Impact Although no clinically significant drug interactions with adjunctive SSRI/SNRIs in MDD were observed in CAPLYTA clinical trials, CAPLYTA’s moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia). * See www.fda.gov/CYPandTransporterInteractingDrugs for examples… (etykieta leku Lumateperon, Interakcje z innymi lekami)